دورية أكاديمية
Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges.
| العنوان: | Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges. |
|---|---|
| المؤلفون: | Brahma MK; Signal Transduction and Metabolism Laboratory, Laboratoire de Gastroentérologie Expérimental et Endotools, Université libre de Bruxelles, Brussels, Belgium., Gilglioni EH; Signal Transduction and Metabolism Laboratory, Laboratoire de Gastroentérologie Expérimental et Endotools, Université libre de Bruxelles, Brussels, Belgium., Zhou L; Materials Research and Education Center, Auburn University, Auburn, AL, 36849, United States., Trépo E; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, C.U.B. Hôpital Erasme, Université libre de Bruxelles, Brussels, Belgium.; Laboratory of Experimental Gastroenterology, Université libre de Bruxelles, Brussels, Belgium., Chen P; Materials Research and Education Center, Auburn University, Auburn, AL, 36849, United States., Gurzov EN; Signal Transduction and Metabolism Laboratory, Laboratoire de Gastroentérologie Expérimental et Endotools, Université libre de Bruxelles, Brussels, Belgium. esteban.gurzov@ulb.be. |
| المصدر: | Oncogene [Oncogene] 2021 Aug; Vol. 40 (33), pp. 5155-5167. Date of Electronic Publication: 2021 Jul 21. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene |
| أسماء مطبوعة: | Publication: <2002->: Basingstoke : Nature Publishing Group Original Publication: Basingstoke, Hampshire, UK : Scientific & Medical Division, MacMillan Press, c1987- |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/etiology , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/metabolism , Liver Neoplasms*/pathology , Liver Neoplasms*/etiology , Liver Neoplasms*/genetics , Obesity*/complications , Obesity*/metabolism , Oxidative Stress* , Signal Transduction* , Reactive Oxygen Species*/metabolism, Humans ; Animals |
| مستخلص: | Obesity affects more than 650 million individuals worldwide and is a well-established risk factor for the development of hepatocellular carcinoma (HCC). Oxidative stress can be considered as a bona fide tumor promoter, contributing to the initiation and progression of liver cancer. Indeed, one of the key events involved in HCC progression is excessive levels of reactive oxygen species (ROS) resulting from the fatty acid influx and chronic inflammation. This review provides insights into the different intracellular sources of obesity-induced ROS and molecular mechanisms responsible for hepatic tumorigenesis. In addition, we highlight recent findings pointing to the role of the dysregulated activity of BCL-2 proteins and protein tyrosine phosphatases (PTPs) in the generation of hepatic oxidative stress and ROS-mediated dysfunctional signaling, respectively. Finally, we discuss the potential and challenges of novel nanotechnology strategies to prevent ROS formation in obesity-associated HCC. (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.) |
| References: | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. (PMID: 3353833810.3322/caac.21660) El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27. (PMID: 2199212410.1056/NEJMra1001683) Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. (PMID: 2893029510.1038/nrgastro.2017.109) Baffy G. Hepatocellular carcinoma in obesity: finding a needle in the haystack? Adv Exp Med Biol. 2018;1061:63–77. (PMID: 2995620710.1007/978-981-10-8684-7_6) Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411–28. (PMID: 3102835010.1038/s41575-019-0145-7) Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99–128. (PMID: 3034332010.1007/s00018-018-2947-0) Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol. 2021;18:45–56. (PMID: 3304133810.1038/s41423-020-00558-8) Raza S, Rajak S, Anjum B, Sinha RA. Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. Hepatoma Res. 2019;5:42. (PMID: 318674416924993) Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21:363–383. (PMID: 3223126310.1038/s41580-020-0230-3) Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive oxygen species in metabolic and inflammatory signaling. Circ Res. 2018;122:877–902. (PMID: 29700084592682510.1161/CIRCRESAHA.117.311401) Liang S, Kisseleva T, Brenner DA. The role of NADPH oxidases (NOXs) in liver fibrosis and the activation of myofibroblasts. Front Physiol. 2016;7:17. (PMID: 26869935473544810.3389/fphys.2016.00017) Sunny NE, Bril F, Cusi K. Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies. Trends Endocrinol Metab. 2017;28:250–60. (PMID: 2798646610.1016/j.tem.2016.11.006) Bellanti F, Villani R, Facciorusso A, Vendemiale G, Serviddio G. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radic Biol Med. 2017;111:173–85. (PMID: 2810989210.1016/j.freeradbiomed.2017.01.023) Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21:739–46. (PMID: 2595520910.1016/j.cmet.2015.04.004) Fransen M, Lismont C, Walton P. The peroxisome-mitochondria connection: How and why? Int J Mol Sci. 2017;18:1126. (PMID: 548595010.3390/ijms18061126) Lismont C, Nordgren M, Van Veldhoven PP, Fransen M. Redox interplay between mitochondria and peroxisomes. Front Cell Dev Biol. 2015;3:35. (PMID: 26075204444496310.3389/fcell.2015.00035) Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J. 2008;275:3278–89. (PMID: 1851332310.1111/j.1742-4658.2008.06489.x) Loughran PA, Stolz DB, Vodovotz Y, Watkins SC, Simmons RL, Billiar TR. Monomeric inducible nitric oxide synthase localizes to peroxisomes in hepatocytes. Proc Natl Acad Sci USA. 2005;102:13837–42. (PMID: 16172396121683010.1073/pnas.0503926102) Stolz DB, Zamora R, Vodovotz Y, Loughran PA, Billiar TR, Kim YM, et al. Peroxisomal localization of inducible nitric oxide synthase in hepatocytes. Hepatology. 2002;36:81–93. (PMID: 1208535210.1053/jhep.2002.33716) Cao SS, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Signal. 2014;21:396–413. (PMID: 24702237407699210.1089/ars.2014.5851) Yoboue ED, Sitia R, Simmen T. Redox crosstalk at endoplasmic reticulum (ER) membrane contact sites (MCS) uses toxic waste to deliver messages. Cell Death Dis. 2018;9:331. (PMID: 29491367583243310.1038/s41419-017-0033-4) Bettaieb A, Jiang JX, Sasaki Y, Chao TI, Kiss Z, Chen X, et al. Hepatocyte nicotinamide adenine dinucleotide phosphate reduced oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of steatohepatitis in mice. Gastroenterology. 2015;149:468–80 e410. (PMID: 2588833010.1053/j.gastro.2015.04.009) Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 2014;26:331–43. (PMID: 25132496416561110.1016/j.ccr.2014.07.001) Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol. 2012;56:448–54. (PMID: 2175684910.1016/j.jhep.2011.05.029) Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, et al. The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int. 2015;35:1574–80. (PMID: 2535129010.1111/liv.12707) Emdin CA, Haas ME, Khera AV, Aragam K, Chaffin M, Klarin D, et al. A missense variant in mitochondrial amidoxime reducing component 1 gene and protection against liver disease. PLoS Genet. 2020;16:e1008629. (PMID: 32282858720000710.1371/journal.pgen.1008629) Sparacino-Watkins CE, Tejero J, Sun B, Gauthier MC, Thomas J, Ragireddy V, et al. Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2. J Biol Chem. 2014;289:10345–58. (PMID: 24500710403615810.1074/jbc.M114.555177) Schneider J, Girreser U, Havemeyer A, Bittner F, Clement B. Detoxification of trimethylamine N-oxide by the mitochondrial amidoxime reducing component mARC. Chem Res Toxicol. 2018;31:447–53. (PMID: 2985659810.1021/acs.chemrestox.7b00329) Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18. (PMID: 2056169910.1016/j.jhep.2010.03.026) Brown KE, Brunt EM, Heinecke JW. Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol. 2001;159:2081–8. (PMID: 11733358185061510.1016/S0002-9440(10)63059-3) Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C, et al. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology. 2009;50:1484–93. (PMID: 1973123710.1002/hep.23187) Nishida N, Yada N, Hagiwara S, Sakurai T, Kitano M, Kudo M. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31:1646–53. (PMID: 2687569810.1111/jgh.13318) Tummala KS, Gomes AL, Yilmaz M, Grana O, Bakiri L, Ruppen I, et al. Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. Cancer Cell. 2014;26:826–39. (PMID: 2545390110.1016/j.ccell.2014.10.002) Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44:694–8. (PMID: 22561517381925110.1038/ng.2256) Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12:564–71. (PMID: 2281081110.1038/nrc3278) Broadfield LA, Duarte JAG, Schmieder R, Broekaert D, Veys K, Planque M, et al. Fat induces glucose metabolism in nontransformed liver cells and promotes liver tumorigenesis. Cancer Res. 2021;81:1988–2001. (PMID: 3368794710.1158/0008-5472.CAN-20-19547611295) Lally JSV, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R, et al. Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019;29:174–82 e175. (PMID: 3024497210.1016/j.cmet.2018.08.020) Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, et al. mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell. 2017;32:807–23 e812. (PMID: 2923255510.1016/j.ccell.2017.11.011) Liu MX, Jin L, Sun SJ, Liu P, Feng X, Cheng ZL, et al. Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma. Oncogene. 2018;37:1637–53. (PMID: 29335519586093010.1038/s41388-017-0070-6) Bian XL, Chen HZ, Yang PB, Li YP, Zhang FN, Zhang JY, et al. Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation. Nat Commun. 2017;8:14420. (PMID: 28240261533336310.1038/ncomms14420) Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59:898–910. (PMID: 2381384210.1002/hep.26592) Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12:408–15. (PMID: 21478880409039110.1038/ni.2022) Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X, et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab Invest. 2014;94:52–62. (PMID: 2416618710.1038/labinvest.2013.126) Loh K, Deng H, Fukushima A, Cai X, Boivin B, Galic S, et al. Reactive oxygen species enhance insulin sensitivity. Cell Metab. 2009;10:260–72. (PMID: 19808019289228810.1016/j.cmet.2009.08.009) Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, et al. The NAD(P)H oxidase homolog nox4 modulates insulin-stimulated generation of H Tiganis T. Reactive oxygen species and insulin resistance: the good, the bad and the ugly. Trends Pharm Sci. 2011;32:82–89. (PMID: 2115938810.1016/j.tips.2010.11.006) DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475:106–9. (PMID: 21734707340447010.1038/nature10189) Tao J, Krutsenko Y, Moghe A, Singh S, Poddar M, Bell A, et al. Nrf2 and beta-catenin coactivation in hepatocellular cancer: biological and therapeutic implications. Hepatology. 2021. https://doi.org/10.1002/hep.31730 . Taniguchi K, Karin M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18:309–24. (PMID: 2937921210.1038/nri.2017.142) Luedde T, Schwabe RF. NF-kappaB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:108–18. (PMID: 21293511329553910.1038/nrgastro.2010.213) Scotcher J, Clarke DJ, Weidt SK, Mackay CL, Hupp TR, Sadler PJ, et al. Identification of two reactive cysteine residues in the tumor suppressor protein p53 using top-down FTICR mass spectrometry. J Am Soc Mass Spectrom. 2011;22:888–97. (PMID: 2147252310.1007/s13361-011-0088-x) Liu D, Xu Y. p53 Oxidative stress and aging. Antioxid Redox Signal. 2011;15:1669–78. (PMID: 21050134315142710.1089/ars.2010.3644) Tomita K, Teratani T, Suzuki T, Oshikawa T, Yokoyama H, Shimamura K, et al. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice. J Hepatol. 2012;57:837–43. (PMID: 2264109510.1016/j.jhep.2012.05.013) Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A, Wands JR. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol. 2013;58:785–91. (PMID: 2321131710.1016/j.jhep.2012.11.042) Kim TH, Kim YE, Ahn S, Kim JY, Ki CS, Oh YL, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr Relat Cancer. 2016;23:813–23. (PMID: 2752862410.1530/ERC-16-0219) Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014;61:1397–1406. (PMID: 2515798310.1016/j.jhep.2014.08.025) Gross A, Katz SG. Non-apoptotic functions of BCL-2 family proteins. Cell Death Differ. 2017;24:1348–58. (PMID: 28234359552045210.1038/cdd.2017.22) Ramalho RM, Cortez-Pinto H, Castro RE, Sola S, Costa A, Moura MC, et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2006;18:21–9. (PMID: 1635761510.1097/00042737-200601000-00005) Lee S, Kim S, Hwang S, Cherrington NJ, Ryu DY. Dysregulated expression of proteins associated with ER stress, autophagy and apoptosis in tissues from nonalcoholic fatty liver disease. Oncotarget. 2017;8:63370–81. (PMID: 28968997560992910.18632/oncotarget.18812) Litwak SA, Pang L, Galic S, Igoillo-Esteve M, Stanley WJ, Turatsinze JV, et al. JNK activation of BIM promotes hepatic oxidative stress, steatosis, and insulin resistance in obesity. Diabetes. 2017;66:2973–86. (PMID: 2892827710.2337/db17-0348) Bedoui S, Herold MJ, Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat Rev Mol Cell Biol. 2020;21:678–95. (PMID: 3287392810.1038/s41580-020-0270-8) Marquardt JU, Edlich F. Predisposition to apoptosis in hepatocellular carcinoma: from mechanistic insights to therapeutic strategies. Front Oncol. 2019;9:1421. (PMID: 31921676692325210.3389/fonc.2019.01421) Kanda T, Matsuoka S, Yamazaki M, Shibata T, Nirei K, Takahashi H, et al. Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol. 2018;24:2661–72. (PMID: 29991872603414610.3748/wjg.v24.i25.2661) Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65–80. (PMID: 2914910010.1038/cdd.2017.186) Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 2003;424:952–6. (PMID: 1293119110.1038/nature01825) Susnow N, Zeng L, Margineantu D, Hockenbery DM. Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol. 2009;19:42–9. (PMID: 1913874210.1016/j.semcancer.2008.12.002) Wali JA, Galic S, Tan CY, Gurzov EN, Frazier AE, Connor T, et al. Loss of BIM increases mitochondrial oxygen consumption and lipid oxidation, reduces adiposity and improves insulin sensitivity in mice. Cell Death Differ. 2018;25:217–25. (PMID: 2905314110.1038/cdd.2017.168) Giordano A, Calvani M, Petillo O, Grippo P, Tuccillo F, Melone MA, et al. tBid induces alterations of mitochondrial fatty acid oxidation flux by malonyl-CoA-independent inhibition of carnitine palmitoyltransferase-1. Cell Death Differ. 2005;12:603–13. (PMID: 1584637310.1038/sj.cdd.4401636) Danial NN, Walensky LD, Zhang CY, Choi CS, Fisher JK, Molina AJ, et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med. 2008;14:144–53. (PMID: 18223655391823210.1038/nm1717) Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018:9547613. (PMID: 29991976601617210.1155/2018/9547613) Glick D, Zhang W, Beaton M, Marsboom G, Gruber M, Simon MC, et al. BNip3 regulates mitochondrial function and lipid metabolism in the liver. Mol Cell Biol. 2012;32:2570–84. (PMID: 22547685343450210.1128/MCB.00167-12) Li X, Wang J, Gong X, Zhang M, Kang S, Shu B, et al. Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. Nucleic Acids Res. 2020;48:8255–68. (PMID: 32710621747098210.1093/nar/gkaa615) Li D, Ueta E, Kimura T, Yamamoto T, Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci. 2004;95:644–650. (PMID: 1529872610.1111/j.1349-7006.2004.tb03323.x) Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell. 2018;34:879–91. (PMID: 3053751110.1016/j.ccell.2018.11.004) Bourebaba L, Lyczko J, Alicka M, Bourebaba N, Szumny A, Fal AM, et al. Inhibition of protein-tyrosine phosphatase PTP1B and LMPTP promotes palmitate/oleate-challenged HepG2 cell survival by reducing lipoapoptosis, improving mitochondrial dynamics and mitigating oxidative and endoplasmic reticulum stress. J Clin Med. 2020;9:1294. (PMID: 728831410.3390/jcm9051294) Hsu MF, Koike S, Mello A, Nagy LE, Haj FG. Hepatic protein-tyrosine phosphatase 1B disruption and pharmacological inhibition attenuate ethanol-induced oxidative stress and ameliorate alcoholic liver disease in mice. Redox Biol. 2020;36:101658. (PMID: 32769011740836110.1016/j.redox.2020.101658) Mobasher MA, Gonzalez-Rodriguez A, Santamaria B, Ramos S, Martin MA, Goya L, et al. Protein tyrosine phosphatase 1B modulates GSK3beta/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity. Cell Death Dis. 2013;4:e626. (PMID: 23661004367435910.1038/cddis.2013.150) Fukushima A, Loh K, Galic S, Fam B, Shields B, Wiede F, et al. T-cell protein tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to regulate gluconeogenesis. Diabetes. 2010;59:1906–14. (PMID: 20484139291107010.2337/db09-1365) Dubois MJ, Bergeron S, Kim HJ, Dombrowski L, Perreault M, Fournes B, et al. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med. 2006;12:549–56. (PMID: 1661734910.1038/nm1397) Xu E, Charbonneau A, Rolland Y, Bellmann K, Pao L, Siminovitch KA, et al. Hepatocyte-specific Ptpn6 deletion protects from obesity-linked hepatic insulin resistance. Diabetes. 2012;61:1949–58. (PMID: 22698917340232510.2337/db11-1502) Matsuo K, Delibegovic M, Matsuo I, Nagata N, Liu S, Bettaieb A, et al. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2. J Biol Chem. 2010;285:39750–58. (PMID: 20841350300095610.1074/jbc.M110.153734) Cho CY, Koo SH, Wang Y, Callaway S, Hedrick S, Mak PA, et al. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metab. 2006;3:367–78. (PMID: 1667929410.1016/j.cmet.2006.03.006) Kim M, Baek M, Kim DJ. Protein tyrosine signaling and its potential therapeutic implications in carcinogenesis. Curr Pharm Des. 2017;23:4226–46. (PMID: 28625132674570810.2174/1381612823666170616082125) Huang Y, Zhang Y, Ge L, Lin Y, Kwok HF. The roles of protein tyrosine phosphatases in hepatocellular carcinoma. Cancers. 2018;10:82. (PMID: 587665710.3390/cancers10030082) Meng T-C, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002;9:387–99. (PMID: 1186461110.1016/S1097-2765(02)00445-8) Bhattacharya S, Labutti JN, Seiner DR, Gates KS. Oxidative inactivation of protein tyrosine phosphatase 1B by organic hydroperoxides. Bioorg Med Chem Lett. 2008;18:5856–9. (PMID: 18595691281912210.1016/j.bmcl.2008.06.029) Ostman A, Frijhoff J, Sandin A, Böhmer FD. Regulation of protein tyrosine phosphatases by reversible oxidation. J Biochem. 2011;150:345–56. (PMID: 2185673910.1093/jb/mvr104) Gurzov EN, Stanley WJ, Brodnicki TC, Thomas HE. Protein tyrosine phosphatases: molecular switches in metabolism and diabetes. Trends Endocrinol Metab. 2015;26:30–9. (PMID: 2543246210.1016/j.tem.2014.10.004) Lou YW, Chen YY, Hsu SF, Chen RK, Lee CL, Khoo KH, et al. Redox regulation of the protein tyrosine phosphatase PTP1B in cancer cells. FEBS J. 2008;275:69–88. (PMID: 1806757910.1111/j.1742-4658.2007.06173.x) Boivin B, Zhang S, Arbiser JL, Zhang ZY, Tonks NK. A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proc Natl Acad Sci USA. 2008;105:9959–64. (PMID: 18632564248134010.1073/pnas.0804336105) Hussein UK, Park HS, Bae JS, Kim KM, Chong YJ, Kim CY, et al. Expression of oxidized protein tyrosine phosphatase and gammaH2AX predicts poor survival of gastric carcinoma patients. BMC Cancer. 2018;18:836. (PMID: 30126387610292610.1186/s12885-018-4752-4) Gurzov EN, Tran M, Fernandez-Rojo MA, Merry TL, Zhang X, Xu Y, et al. Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2. Cell Metab. 2014;20:85–102. (PMID: 24954415433526710.1016/j.cmet.2014.05.011) Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, Butt T, et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell. 2018;175:1289–1306 e1220. (PMID: 30454647624246710.1016/j.cell.2018.09.053) Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61:1226–33. (PMID: 27003142778991410.1007/s10620-016-4095-4) Haque A, Andersen JN, Salmeen A, Barford D, Tonks NK. Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell. 2011;147:185–98. (PMID: 21962515320030910.1016/j.cell.2011.08.036) Krishnan N, Bonham CA, Rus IA, Shrestha OK, Gauss CM, Haque A, et al. Harnessing insulin- and leptin-induced oxidation of PTP1B for therapeutic development. Nat Commun. 2018;9:283. (PMID: 29348454577348710.1038/s41467-017-02252-2) Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293–13. (PMID: 3351046010.1038/s41575-020-00395-0) Nakajima W, Tanaka N. BH3 mimetics: their action and efficacy in cancer chemotherapy. Integr Cancer Sci Therapeutics. 2016;3:437–41. (PMID: 10.15761/ICST.1000184) Bartneck M, Warzecha KT, Tacke F. Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg Nutr. 2014;3:364–76. (PMID: 255688604273112) Nisha R, Kumar P, Kumar U, Mishra N, Maurya P, Singh S, et al. Fabrication of imatinib mesylate-loaded lactoferrin-modified PEGylated liquid crystalline nanoparticles for mitochondrial-dependent apoptosis in hepatocellular carcinoma. Mol Pharmaceutics. 2020;18:1102–20. (PMID: 10.1021/acs.molpharmaceut.0c01024) Cao N, Cheng D, Zou S, Ai H, Gao J, Shuai X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials. 2011;32:2222–32. (PMID: 2118605910.1016/j.biomaterials.2010.11.061) Zhou Y, Li K, Li F, Han S, Wang Y, Li X, et al. Doxorubicin and ABT-199 coencapsulated nanocarriers for targeted delivery and synergistic treatment against hepatocellular carcinoma. J Nanomaterials. 2019;2019:1–13. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjugate Chem. 2011;22:1879–903. (PMID: 10.1021/bc200151q) Ye Z, Wu W, Qin Y, Hu J, Liu C, Seeberger PH, et al. An integrated therapeutic delivery system for enhanced treatment of hepatocellular carcinoma. Adv Funct Mater. 2018;28:1706600. (PMID: 10.1002/adfm.201706600) Tanaka T, Yamanaka N, Oriyama T, Furukawa K, Okamoto E. Factors regulating tumor pressure in hepatocellular carcinoma and implications for tumor spread. Hepatology. 1997;26:283–7. (PMID: 925213510.1002/hep.510260205) Ke PC, Lin S, Parak WJ, Davis TP, Caruso F. A decade of the protein corona. ACS Nano. 2017;11:11773–6. (PMID: 2920603010.1021/acsnano.7b08008) Dai Q, Walkey C, Chan WCW. Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting. Angew Chem Int Ed. 2014;53:5093–6. (PMID: 10.1002/anie.201309464) D’Hollander A, Jans H, Velde GV, Verstraete C, Massa S, Devoogdt N, et al. Limiting the protein corona: a successful strategy for in vivo active targeting of anti-HER2 nanobody-functionalized nanostars. Biomaterials. 2017;123:15–23. (PMID: 2815238010.1016/j.biomaterials.2017.01.007) Kumar M, Gupta D, Singh G, Sharma S, Bhat M, Prashant CK, et al. Novel polymeric nanoparticles for intracellular delivery of peptide cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res. 2014;74:3271–81. (PMID: 24741005408998210.1158/0008-5472.CAN-13-2015) Kumar P, Gautam AK, Kumar U, Bhadauria AS, Singh AK, Kumar D, et al. Mechanistic exploration of the activities of poly(lactic-co-glycolic acid)-loaded nanoparticles of betulinic acid against hepatocellular carcinoma at cellular and molecular levels. Arch Physiol Biochem 2020:1–13. Huang Y, Zhou B, Luo H, Mao J, Huang Y, Zhang K, et al. ZnAs@SiO(2) nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling. Theranostics. 2019;9:4391–408. (PMID: 31285768659964910.7150/thno.32462) Khan AA, Alanazi AM, Jabeen M, Hassan I, Bhat MA. Targeted nano-delivery of novel omega-3 conjugate against hepatocellular carcinoma: regulating COX-2/bcl-2 expression in an animal model. Biomedicine Pharmacother. 2016;81:394–401. (PMID: 10.1016/j.biopha.2016.04.033) Li X, Zhang H, Zheng D, Ding J, Xu H, Sun W. Efficient delivery of ursolic acid by poly(N-vinylpyrrolidone)-block-poly (ε-caprolactone) nanoparticles for inhibiting the growth of hepatocellular carcinoma in vitro and in vivo. Int J Nanomed. 2015;10:1909–20. (PMID: 10.2147/IJN.S77125) Yu M, Han S, Kou Z, Dai J, Liu J, Wei C, et al. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance. Artif Cells Nanomed Biotechnol. 2018;46:323–32. (PMID: 2839356310.1080/21691401.2017.1307215) Cheng H, Wu Z, Wu C, Wang X, Liow SS, Li Z, et al. Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells. Mater Sci Eng: C. 2018;83:210–17. (PMID: 10.1016/j.msec.2017.08.075) Tian G, Pan R, Zhang B, Qu M, Lian B, Jiang H, et al. Liver-targeted combination therapy basing on glycyrrhizic acid-modified DSPE-PEG-PEI nanoparticles for co-delivery of doxorubicin and Bcl-2 siRNA. Front Pharmacol. 2019;10:1–13. (PMID: 10.3389/fphar.2019.00004) Kim J, Shim MK, Yang S, Moon Y, Song S, Choi J, et al. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance. J Controll Release. 2020;330:920–32. (PMID: 10.1016/j.jconrel.2020.10.065) Ning Q, Liu Y, Ye P, Gao P, Li Z, Tang S, et al. Delivery of liver-specific miRNA-122 using a targeted macromolecular prodrug toward synergistic therapy for hepatocellular carcinoma. ACS Appl Mater Interfaces. 2019;11:10578–88. (PMID: 3080202910.1021/acsami.9b00634) Liu M, Tu J, Feng Y, Zhang J, Wu J. Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma. J Nanobiotechnology. 2020;18:114. (PMID: 32811502743707310.1186/s12951-020-00677-4) |
| معلومات مُعتمدة: | R35 GM133795 United States GM NIGMS NIH HHS |
| المشرفين على المادة: | 0 (Reactive Oxygen Species) |
| تواريخ الأحداث: | Date Created: 20210722 Date Completed: 20240724 Latest Revision: 20240724 |
| رمز التحديث: | 20240726 |
| مُعرف محوري في PubMed: | PMC9277657 |
| DOI: | 10.1038/s41388-021-01950-y |
| PMID: | 34290399 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1476-5594 |
|---|---|
| DOI: | 10.1038/s41388-021-01950-y |